[Form 4] Elanco Animal Health Incorporated Insider Trading Activity

Rhea-AI Filing Summary

Elanco Animal Health Inc.'s President, CEO and Director Jeffrey N. Simmons acquired 166.1212 deferred stock units on 08/08/2025 under the company's Executive Deferral and Stock Match Plan. Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent. After the reported acquisition, Mr. Simmons beneficially owns 17,387.0337 common stock-equivalent units on a direct basis. The deferred units may settle in cash or shares following termination of employment or during a specified future year.

Positive

• Acquisition of 166.1212 deferred stock units, increasing direct beneficial ownership to 17,387.0337 common-equivalent units
• Deferred units align executive compensation with shareholders by converting to shares or cash under the Executive Deferral and Stock Match Plan

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine executive deferral increases direct beneficial ownership, aligning CEO compensation with shareholder outcomes.

The filing documents an equity deferral acquisition by the company's President and CEO, adding 166.1212 deferred stock units and bringing direct beneficial ownership to 17,387.0337 units. This is consistent with standard executive compensation practices that defer equity compensation for future settlement and can strengthen alignment between executive pay and long-term shareholder value. The form shows the units may settle in cash or shares under the Executive Deferral and Stock Match Plan, which is a typical settlement feature that preserves flexibility for the company and participant.

Compensation Analyst

TL;DR: Small incremental grant recorded; settlement terms and per-unit price are disclosed but no disposition or cash payout now.

The report records an acquisition of 166.1212 deferred stock units with an indicated per-unit amount of $16.67 and updates total holdings to 17,387.0337 units. The disclosure specifies deferred units convert to one share each or cash equivalent and settle post-termination or in a designated future year per plan rules. There is no sale or exercise reported, so this represents deferred compensation recognition rather than a current liquidity event.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simmons Jeffrey N

(Last) (First) (Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

2500 INNOVATION WAY

(Street)

GREENFIELD IN 46140

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT, CEO AND DIRECTOR

3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Stock Units	(1)	08/08/2025		A		166.1212		(2)	(2)	Common Stock	166.1212	$16.67	17,387.0337	D

Explanation of Responses:

1. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.

2. Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

	/s/ Amy C. Seidel, as Attorney-in-Fact for Jeffrey N. Simmons	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Jeffrey N. Simmons report on the ELAN Form 4?

He reported acquiring 166.1212 deferred stock units on 08/08/2025, bringing his direct beneficial ownership to 17,387.0337 common-equivalent units.

What are the settlement terms for the deferred stock units in the ELAN filing?

The deferred stock units represent the right to one share of common stock or the cash equivalent and settle in cash or shares following termination or during a specified future year under the Executive Deferral and Stock Match Plan.

Does the ELAN Form 4 show any sales or dispositions by Jeffrey N. Simmons?

No. The Form 4 shows an acquisition (A) of deferred stock units; there are no sales or dispositions reported in this filing.

What per-unit amount is disclosed for the deferred stock units on the ELAN Form 4?

The table in the filing indicates a per-unit figure of $16.67 associated with the reported deferred stock units.

What roles does the reporting person hold at Elanco (ELAN)?

The reporting person, Jeffrey N. Simmons, is identified as President, CEO and Director of Elanco Animal Health Inc.